Regulation of p53 protein biosignatures in acute myeloid leukemia by signal transduction networks: impact of signal integration in chemoresistance and individualized therapy
- Prosjektnummer
- 911307
- Ansvarlig person
- Bjørn Tore Gjertsen
- Institusjon
- Universitetet i Bergen
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Hematology
- Forskningsaktivitet
- Translasjonsforskning
Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death.
Blood 2008 Mar;111(5):2866-77. Epub 2008 jan 8
PMID: 18182573
Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels.
Leukemia 2008 Feb;22(2):287-93. Epub 2007 okt 18
PMID: 17943167
Review: genetic models of acute myeloid leukaemia.
Oncogene 2008 Jun;27(27):3765-79. Epub 2008 feb 11
PMID: 18264136
In vivo biological effects of ATRA in the treatment of AML.
Expert Opin Investig Drugs 2008 Nov;17(11):1623-33.
PMID: 18922099
A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
Leuk Res 2009 Jun;33(6):779-87. Epub 2008 nov 12
PMID: 19007987
Anticancer immunotherapy in combination with proapoptotic therapy.
Curr Cancer Drug Targets 2008 Dec;8(8):666-75.
PMID: 19075589
Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts.
Eur J Oral Sci 2008 Feb;116(1):23-30.
PMID: 18186728
Erythropoietin a safe bet in haemorrhagic shock?
Acta Anaesthesiol Scand 2008 May;52(5):585-6.
PMID: 18419707
Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.
Blood 2007 Mar;109(6):2589-96. Epub 2006 nov 14
PMID: 17105820
T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005.
Cancer Immunol Immunother 2007 Jun;56(6):913-25. Epub 2006 nov 8
PMID: 17115221
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.
Haematologica 2007 Mar;92(3):332-41.
PMID: 17339182
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
Br J Haematol 2007 Mar;136(6):814-28.
PMID: 17341267
Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.
Anal Biochem 2007 Jul;366(1):46-58. Epub 2007 mar 18
PMID: 17449007
LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.
Mol Cancer 2007;6():31. Epub 2007 apr 23
PMID: 17451600
Early gene expression of acute myeloid leukemia in response to chemotherapy.
Expert Rev Anticancer Ther 2007 May;7(5):741-51.
PMID: 17492937
Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
Mol Cancer 2007;6():33. Epub 2007 mai 11
PMID: 17498302
In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization.
Mol Imaging 2007 May-Jun;6(3):193-204.
PMID: 17532885
Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex.
Hematology 2007 Jun;12(3):199-207.
PMID: 17558695
Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
Eur J Haematol 2007 Sep;79(3):210-25. Epub 2007 jul 26
PMID: 17655707
Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling.
Expert Opin Ther Targets 2007 Aug;11(8):1055-69.
PMID: 17665978
Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.
Int J Oncol 2007 Dec;31(6):1529-38.
PMID: 17982680
Effects of interferon gamma on native human acute myelogenous leukaemia cells.
Cancer Immunol Immunother 2007 Jan;56(1):13-24. Epub 2006 apr 13
PMID: 16612597
CaM-kinaseII-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation.
Cell Death Differ 2006 Jul;13(7):1191-202. Epub 2005 nov 25
PMID: 16311514
Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report.
Leukemia 2006 Apr;20(4):734-6.
PMID: 16437140
Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.
Expert Opin Ther Targets 2006 Feb;10(1):51-68.
PMID: 16441228
cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
Int J Oncol 2006 May;28(5):1065-80.
PMID: 16596222
Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90.
Leuk Res 2006 Dec;30(12):1531-40. Epub 2006 apr 5
PMID: 16600371
Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables.
BMC Bioinformatics 2006;7():198. Epub 2006 apr 10
PMID: 16606449
Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia.
Acta Oncol 2006;45(3):346-9.
PMID: 16644583
Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML).
Curr Pharm Biotechnol 2006 Jun;7(3):159-70.
PMID: 16789901
Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies.
Curr Pharm Biotechnol 2006 Jun;7(3):185-98.
PMID: 16789903
Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia.
Curr Pharm Biotechnol 2006 Jun;7(3):199-207.
PMID: 16789904
A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia.
Clin Cancer Res 2006 Jul;12(13):3985-92.
PMID: 16818696
Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment.
Electrophoresis 2006 Oct;27(20):4086-95.
PMID: 16983632
Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics
“Genomic and Personalized Medicine” edited by Hunt Willard and Geoff Ginsburg. ELSEVIER / Academic Press, 2008.
Synergistic Anti-Leukemic Effect of Protein Kinase A Activator and PPAR Agonist Is Independent of Bcl-2 Status.
Blood (ASH Annual Meeting Abstracts), Nov 2007
Discrimination and Quantification of Spectrally Similar Near-Infrared Probes by Time-Domain (TD) Optical Imaging in AML models
Blood (ASH Annual Meeting Abstracts), Nov 2007.
Flt3 Mutations in Proximity to an Ubiquitin Dependent Endocytosis Motif Suspend Its Hdm2 Modulation.
Blood (ASH Annual Meeting Abstracts), Nov 2007.
Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
Blood (ASH Annual Meeting Abstracts), Nov 2007.
Development and evaluation of labeled antibodies as optical contrast reagents in acute myeloid leukemia (AML)
Joint Molecular Imaging Conference, Providence, Rhode Island, USA, Sept 8-11 2007
In vivo optical imaging of p53 specific targeted therapy in Acute Myeloid Leukaemia
Joint Molecular Imaging Conference, Providence, Rhode Island, USA, Sept 8-11 2007
Development of a near infrared reporter system for in vivo imaging
Joint Molecular Imaging Conference, Providence, Rhode Island, USA, Sept 8-11 2007
Early protein and gene modulation in response to induction chemotherapy of acute myeloid leukemia
Oral presentation, 12th World Congress on Advances in Oncology, Hersonissos, Crete, Greece, 11-13/10-2007
Early Protein and Gene Modulation in Response to Induction Chemotherapy of Acute Myeloid Leukemia
Lecture, Yale School of Medicine’s Department of Laboratory Medicine 12/12-2007
Modulation of apoptosis by the receptor tyrosine kinase Flt3 in acute myeloid leukemia cells
- Disputert:
- oktober 2008
- Hovedveileder:
- Kari Fladmark
New strategies in the treatment of acute myeloid leukaemia
- Disputert:
- april 2008
- Hovedveileder:
- Øystein Bruserud
Immunological aspects of acute myelogenous leukemia
- Disputert:
- februar 2007
- Hovedveileder:
- Øystein Bruserud
Flt3 receptor tyrosine kinase in AML and its modulation of the p53/Hdm2/Bcl-2 pathway
- Disputert:
- september 2007
- Hovedveileder:
- Bjørn Tore Gjertsen
New lessons from an “old” drug: A proteomic study of anthracycline-induced apoptosis in AML
- Disputert:
- desember 2007
- Hovedveileder:
- Bjørn Tore Gjertsen
p53 protein biosignatures in acute myeloid leukemia
- Disputert:
- mars 2006
- Hovedveileder:
- Bjørn Tore Gjertsen
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest